Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial

Diabetologia

Volumn 59, Issue 12, 2016, Pages 2579-2587

  Ott, Christian ^a   Kistner, Iris ^a   Keller, Mirjam ^a   Friedrich, Stefanie ^a   Willam, Carsten ^a   Bramlage, Peter ^b   Schmieder, Roland E ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b Institute for Pharmacology and Preventive Medicine   (Germany)

Author keywords

DPP 4 inhibitor; Endothelial function; Nitric oxide; Renal; Type 2 diabetes

Indexed keywords

ALBUMIN; ARGININE; CREATININE; GLUCOSE; HEMOGLOBIN A1C; LINAGLIPTIN; N(G) METHYLARGININE; NITRIC OXIDE SYNTHASE; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADULT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDOTHELIUM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY PLASMA FLOW; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; RENAL CLEARANCE; TREATMENT DURATION; UPREGULATION; AGED; ALBUMINURIA; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLOMERULUS FILTRATION RATE; HYPERGLYCEMIA; KIDNEY; METABOLISM; PHYSIOLOGY; TREATMENT OUTCOME; URINE;

AGED; ALBUMINURIA; BLOOD GLUCOSE; CREATININE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; KIDNEY; LINAGLIPTIN; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; TREATMENT OUTCOME;

EID: 84984791882     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-016-4083-4     Document Type: Article

References (41)

1. Redon J, Morales-Olivas F, Galgo A et al (2006) Urinary albumin excretion and glomerular filtration rate across the spectrum of glucose abnormalities in essential hypertension. J Am Soc Nephrol 17:S236–S245
2. Ruilope L, Izzo J, Haller H et al (2010) Prevention of microalbuminuria in patients with type 2 diabetes: what do we know? J Clin Hypertens 12:422–430
3. Ott C, Schneider MP, Delles C, Schlaich MP, Schmieder RE (2011) Reduction in basal nitric oxide activity causes albuminuria. Diabetes 60:572–576
4. Ott C, Schlaich MP, Schmidt BM, Titze SI, Schaufele T, Schmieder RE (2008) Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia. Atherosclerosis 196:704–711
5. Ritt M, Ott C, Raff U et al (2009) Renal vascular endothelial function in hypertensive patients with type 2 diabetes mellitus. Am J Kidney Dis 53:281–289
6. Veelken R, Hilgers KF, Hartner A, Haas A, Bohmer KP, Sterzel RB (2000) Nitric oxide synthase isoforms and glomerular hyperfiltration in early diabetic nephropathy. J Am Soc Nephrol 11:71–79
7. Schlaich MP, Schmitt D, Ott C, Schmidt BM, Schmieder RE (2008) Basal nitric oxide synthase activity is a major determinant of glomerular haemodynamics in humans. J Hypertens 26:110–116
8. Holst JJ, Deacon CF (2005) Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 48:612–615
9. Ozyazgan S, Kutluata N, Afsar S, Ozdas SB, Akkan AG (2005) Effect of glucagon-like peptide-1(7-36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats. Pharmacology 74:119–126
10. Shah Z, Pineda C, Kampfrath T et al (2011) Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. Vasc Pharmacol 55:2–9
11. Takai S, Sakonjo H, Jin D (2014) Significance of vascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats. J Pharmacol Sci 125:386–393
12. Koibuchi N, Hasegawa Y, Katayama T et al (2014) DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure. Cardiovasc Diabetol 13:157
13. Nakashima S, Matsui T, Takeuchi M, Yamagishi SI (2014) Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis. Horm Metab Res 46:717–721
14. Schmieder RE, Gatzka C, Schobel H, Schachinger H, Weihprecht H (1994) Renal hemodynamic response to stress is influenced by ACE-inhibitors. Clin Nephrol 42:381–388
15. Delles C, Klingbeil AU, Schneider MP, Handrock R, Schaufele T, Schmieder RE (2004) The role of nitric oxide in the regulation of glomerular haemodynamics in humans. Nephrol Dial Transplant 19:1392–1397
16. Smith HW, Finkelstein N, Aliminosa L, Crawford B, Graber M (1945) The renal clearances of substituted hippuric acid derivatives and other aromatic acids in dog and man. J Clin Invest 24:388–404
17. Gomez DM (1951) Evaluation of renal resistances, with special reference to changes in essential hypertension. J Clin Invest 30:1143–1155
18. Guidi E, Cozzi MG, Minetti EE, Civati G, Busnach G, Brando B (2001) Effect of familial hypertension on glomerular hemodynamics and tubulo-glomerular feedback after uninephrectomy. Am J Hypertens 14:121–128
19. Ott C, Ritt M, Titze SI, Schaufele T, Schmieder RE (2009) Rosuvastatin does not affect intrarenal hemodynamics in patients with hypercholesterolemia. J Nephrol 22:675–681
20. Ott C, Schneider MP, Raff U et al (2013) Effects of manidipine vs. amlodipine on intrarenal haemodynamics in patients with arterial hypertension. Br J Clin Pharmacol 75:129–135
21. Schmieder RE, Delles C, Mimran A, Fauvel JP, Ruilope LM (2007) Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care 30:1351–1356
22. Bank N, Aynedjian HS (1993) Role of EDRF (nitric oxide) in diabetic renal hyperfiltration. Kidney Int 43:1306–1312
23. Chiarelli F, Cipollone F, Romano F et al (2000) Increased circulating nitric oxide in young patients with type 1 diabetes and persistent microalbuminuria: relation to glomerular hyperfiltration. Diabetes 49:1258–1263
24. Choi KC, Kim NH, An MR, Kang DG, Kim SW, Lee J (1997) Alterations of intrarenal renin-angiotensin and nitric oxide systems in streptozotocin-induced diabetic rats. Kidney Int Suppl 60:S23–S27
25. Hohenstein B, Hugo CP, Hausknecht B, Boehmer KP, Riess RH, Schmieder RE (2008) Analysis of NO-synthase expression and clinical risk factors in human diabetic nephropathy. Nephrol Dial Transplant 23:1346–1354
26. Satoh M, Fujimoto S, Haruna Y et al (2005) NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol 288:F1144–F1152
27. Schneider MP, Ott C, Schmidt S, Kistner I, Friedrich S, Schmieder RE (2013) Poor glycemic control is related to increased nitric oxide activity within the renal circulation of patients with type 2 diabetes. Diabetes Care 36:4071–4075
28. Delles C, Schneider MP, Oehmer S, Fleischmann I, Fleischmann EF, Schmieder RE (2004) Increased response of renal perfusion to the antioxidant vitamin C in type 2 diabetes. Nephrol Dial Transplant 19:2513–2518
29. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA (1996) Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 97:22–28
30. Monnier L, Mas E, Ginet C et al (2006) Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295:1681–1687
31. Rizzo MR, Barbieri M, Marfella R, Paolisso G (2012) Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 35:2076–2082
32. Savino A, Pelliccia P, Schiavone C et al (2006) Serum and urinary nitrites and nitrates and Doppler sonography in children with diabetes. Diabetes Care 29:2676–2681
33. − and NO. Am J Physiol Renal Physiol 279:F302–F308
34. Veelken R, Vogel EM, Hilgers K et al (2008) Autonomic renal denervation ameliorates experimental glomerulonephritis. J Am Soc Nephrol 19:1371–1378
35. Sugimoto H, Shikata K, Matsuda M et al (1998) Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy. Diabetologia 41:1426–1434
36. Peralta CA, Katz R, Bonventre JV et al (2012) Associations of urinary levels of kidney injury molecule 1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) with kidney function decline in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis 60:904–911
37. Carlsson AC, Calamia M, Riserus U et al (2014) Kidney injury molecule (KIM)-1 is associated with insulin resistance: results from two community-based studies of elderly individuals. Diabetes Res Clin Pract 103:516–521
38. Sabbisetti VS, Waikar SS, Antoine DJ et al (2014) Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. J Am Soc Nephrol 25:2177–2186
39. Nistala R, Habibi J, Lastra G et al (2014) Prevention of obesity-induced renal injury in male mice by DPP4 inhibition. Endocrinology 155:2266–2276
40. Matsubara J, Sugiyama S, Akiyama E et al (2013) Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J 77:1337–1344
41. Satoh K (2013) Dipeptidyl peptidase-4 inhibitors--emerging player for vascular protection. Circ J 77:1156–1157